tradingkey.logo
tradingkey.logo
Search

Eloxx Pharmaceuticals Ord Shs

ELOX
Add to Watchlist
13.150USD
+0.260+2.02%
Close 11-13 16:00(ET)
53.13MMarket Cap
0.00P/E TTM

About Eloxx Pharmaceuticals Ord Shs Company

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the science of ribosome modulation, leveraging both its TURBO- ZM chemistry technology platform and its library of aminoglycosides to develop oral small-molecule ribosome modulating agents (RMAs) and eukaryotic ribosome selective glycosides (ERSGs) for the treatment of rare and ultra-rare genetic diseases. Its lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. The Company is also advancing ZKN-013 as an oral agent for the treatment of recessive dystrophic (RDEB)/ junctional epidermolysis bullosa (JEB) and familial adenomatous polyposis (FAP) patients with nonsense mutations. The Company also has preclinical programs focused on select rare diseases, including inherited diseases, cancer caused by nonsense mutations, kidney diseases, as well as rare ocular genetic disorders.

Eloxx Pharmaceuticals Ord Shs Profile

Ticker Symbol- -
Company name- -
IPO date- -
CEO- -
Number of employees- -
Security type- -
Fiscal year-end- -
Address- -
City- -
Stock exchange- -
Country- -
Postal code- -
Phone- -
Website- -
Ticker Symbol- -
IPO date- -
CEO- -

Company Executives of Eloxx Pharmaceuticals Ord Shs

Name
Name/Position
Position
Shareholding
Change
Mr. Sumit Aggarwal
Mr. Sumit Aggarwal
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
152.07K
-0.00%
Mr. Steven Rubin, J.D.
Mr. Steven Rubin, J.D.
Independent Director
Independent Director
--
--
Dr. Alan E. Walts, Ph.D.
Dr. Alan E. Walts, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Daniel E. (Dan) Geffken, CPA
Mr. Daniel E. (Dan) Geffken, CPA
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Mr. John Woolford
Mr. John Woolford
Investor Relations Officer
Investor Relations Officer
--
--
Mr. Stephen W. Webster
Mr. Stephen W. Webster
Independent Director
Independent Director
--
--
Ms. Nina Kjellson
Ms. Nina Kjellson
Independent Director
Independent Director
--
--
Mr. Geno J. Germano
Mr. Geno J. Germano
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Sumit Aggarwal
Mr. Sumit Aggarwal
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
152.07K
-0.00%
Mr. Steven Rubin, J.D.
Mr. Steven Rubin, J.D.
Independent Director
Independent Director
--
--
Dr. Alan E. Walts, Ph.D.
Dr. Alan E. Walts, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Daniel E. (Dan) Geffken, CPA
Mr. Daniel E. (Dan) Geffken, CPA
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Mr. John Woolford
Mr. John Woolford
Investor Relations Officer
Investor Relations Officer
--
--
Mr. Stephen W. Webster
Mr. Stephen W. Webster
Independent Director
Independent Director
--
--

FAQs

Who are the top five shareholders of Eloxx Pharmaceuticals Ord Shs?

The top five shareholders of Eloxx Pharmaceuticals Ord Shs are: Mr. Sumit Aggarwal
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.